Extended Data Fig. 7: RIPR-PD1 induces T cells with an effector memory phenotype in a SCLC tumour model.
From: Immune receptor inhibition through enforced phosphatase recruitment
a, Representative analysis of CD44 and CD62L expression in lymphocytes isolated from tumour-proximal lymph nodes collected at day 19 post inoculation with KP1 (SCLC) cells for various treatments, as indicated. Data are representative from n = 5 biological replicates from 2 independent experiments. b, c, Quantification of the representative data shown in a for CD4+ (b) and CD8+ (c) cells. In b, c, data are mean ± s.d. from n = 5 biological replicates representative of 2 independent experiments. d, Quantification of the frequency of CD4+ and CD8+ cells in spleen (left) peripheral (middle) and distal (right) lymph nodes from wild-type mice treated with 200 μg anti-PD1 or RIPR-PD1 every 3 days for one week. e, Quantification of CD4+ and CD8+ infiltrates in brown adipose tissue. Mice were treated as described in d. In d, e, data are mean ± s.d. from n = 3 (d) and n = 5 (e) biological replicates representative of 2 independent experiments. For representative gating strategy, see Supplementary Fig. 2.
